No abstract

No abstract

No abstract

No abstract

This developed SNEP formulations can be regarded as novel and commercially feasible alternative to the current risperidone formulations.

Transdermal drug delivery technology generated tremendous excitement and interest amongst major pharmaceutical companies in the 1980s and 90s. Ethosomes are the ethanolic phospholipid vesicles which are used mainly for transdermal delivery of drugs. Ethosomes have higher penetration rate through the skin as compared to liposomes hence these can be used widely in place of liposomes. Ethosomes have become an area of research interest, because of its enhanced skin permeation, improved drug delivery, increased drug entrapment efficiency etc. The purpose of writing this review on ethosomes drug delivery was to compile the focus on the various aspects of ethosomes including their mechanism of penetration, preparation, advantages, composition, characterization, application and marketed product of ethosomes. Characterizations of ethosomes include Particle size, Zeta potential, Differential Scanning Calorimertry, Entrapment efficiency, Surface tension activity measurement, Vesicle stability and Penetration Studies etc. Introduction:Transdermal drug delivery system (TDDS) showed promising [1] result in comparison to oral drug delivery system as it eliminates gastrointestinal interferences and first pass metabolism of the drug but the main drawback of TDDS is it encounters the barrier properties of the stratum corneum i.e. only the lipophilic drugs having molecular weight < 500 Dacan pass through it.TDDS have been developed in order to enhance the driving force of drug diffusion or increase the permeability of the skin. These approaches [2] include the use of Chinmaya Keshari Sahoo et al /International Journal of ChemTech Research, 2018,11(08): 219-226.

Floating drug delivery system (FDDS) are of particular interest for drugs that are locally active and have narrow absorption window in stomach or upper small intestine, unstable in the intestinal or colonic environment, and exhibit low solubility at high pH values. The Micro sponge Delivery System (MDS) is a patented polymeric system consisting of porous microspheres. These are tiny sponge like spherical particles that consist of a myriad of interconnecting voids within a non-collapsible structure with a large porous surface through which active ingredient are released in a controlled manner. Famotidine floating microsponges are prepared to improve site specific absorption of drug for peptic ulcer treatment. Modified quasi emulsion solvent diffusion method was used to formulate microsponges. Different concentrations of EudragitS100 and Polyvinyl alcohol were used and the prepared microsponges were evaluated for % entrapment efficiency, % buoyancy and % cumulative drug release. It was found that the % entrapment efficiency was 88.3%, % buoyancy was 76.4% and % cumulative drug release was 86.9% for F6 formulation. This study presents a new approach based on floating ability of microsponges for treatment of ulcer.

Objective: Olmesartan belongs to a class of angiotensin II receptor blockers. It is used in the treatment of hypertension. However, it undergoes extensive hepatic first-pass metabolism, resulting in low oral bioavailability is about 26%. The aim of this study was to prepare and evaluate the mucoadhesive buccal tablets of olmesartan with a goal to increase the bioavailability and improve the patient compliance.Methods: Mucoadhesive buccal tablets were prepared by a direct compression technique using mucoadhesive polymers such as hydroxypropyl methylcellulose (HPMC K4M), sodium carboxymethylcellulose (SCMC), and Carbopol 934P. The tablets were evaluated for weight variation, thickness, hardness, friability, surface pH, swelling index, drug content uniformity, in vitro drug release, ex vivo mucoadhesive strength, ex vivo mucoadhesive time, and ex vivo permeation studies. The release kinetics was calculated to determine the drug release mechanism. Results: The physicochemical properties of all the formulations were shown to be within the limits. The optimized buccal tablets F2, F7, and F11 showed satisfactory drug release rates with the diffusion controlled mechanism. Optimized buccal tablets developed for olmesartan possess reasonable mucoadhesive strength, mucoadhesive time, and surface pH was in an acceptable salivary pH 6.76±0.28–6.89±0.34. The ex vivo permeation studies for optimized tablets were shown satisfactory drug permeation and could meet the target flux 0.991 mg h−1cm−2.Conclusion: The obtained results could be used as a platform to develop the buccal delivery of this drug, which bypasses the first-pass metabolism and results in the improvement of bioavailability. Hence, the present study concludes that the olmesartan could be delivered through the buccal route.